Merck: New recommendations call for metformin at diagnosis of type 2 diabetes

By E. Janene Geiss

Philadelphia, Sept. 13 - Merck KgaA said Wednesday that a new recommendation of a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes calls for newly diagnosed patients with diabetes to be treated with metformin (Glucophage) in conjunction with lifestyle modification.

Initiation of metformin should no longer be delayed until lifestyle modification (weight loss and increased activity) fails to adequately control glycemia, the Darmstadt, Germany, pharmaceutical company said in a news release.

Traditionally, guidelines have recommended lifestyle modification as the first step in intervention to reduce glycemia. Now, however, the expert panel has recognized that lifestyle modification alone often fails to achieve or maintain metabolic goals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.